13D Filing: Sarissa Capital Management and Novelion Therapeutics Inc. (NVLN)

Page 5 of 9 – SEC Filing

 


1
NAME OF REPORTING PERSON OR
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Sarissa Capital Catapult Fund LLC
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP


(a)     ¨

(b)     ¨

3

SEC USE ONLY

4 SOURCE OF FUNDS

WC
5

CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS
IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

 ¨
6 CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER
OF

SHARES

BENEFICIALLY

OWNED
BY

EACH

REPORTING

PERSON

WITH

7

SOLE
VOTING POWER

 

617,343

8

SHARED
VOTING POWER

 

 

9

SOLE
DISPOSITIVE POWER

 

617,343

10

SHARED
DISPOSITIVE POWER

 

 

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

617,343
12

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES:

 

¨
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

3.3%
14

TYPE OF REPORTING PERSON

OO

Follow Novelion Therapeutics Inc. (NASDAQ:NVLN)